Atypical femur fractures: Review of epidemiology, relationship to bisphosphonates, prevention, and clinical management

Dennis M. Black, Bo Abrahamsen, Mary L. Bouxsein, Thomas Einhorn, Nicola Napoli

Research output: Contribution to journalReview article

8 Citations (Scopus)

Abstract

Bisphosphonates (BPs) are highly effective in treating osteoporosis and reducing hip, vertebral, and other fractures by as much as 50% to 70%. However, since 2006, atypical femur fractures (AFFs) emerged as potential side effects of BPs and other treatments. These fractures have unusual radiologic features and occur with little trauma. Public concern has led to a >50% decrease in BP usage. AFFs are rare: for each AFF, >1200 fractures, including 135 hip fractures, are prevented. Case definition criteria were updated by the American Society of Bone and Mineral Research in 2014. Many epidemiologic studies have been reported, and although methodologically challenging, generally support a BP-AFF association. However, the magnitude of the association between BPs and AFFs is uncertain: estimates of relative risk for AFFs among BP users vs nonusers range from 1 to 65 with a meta-analysis estimate of 1.7. Although mechanistic studies have proposed several hypotheses explaining how BPs might decrease bone strength, AFF pathogenesis remains uncertain and cannot explain the paradox of efficacy of reduction of common fractures while increasing risk for rare fractures at one site. There are several consistent risk factors, including Asian race (in North America), femoral bowing, and glucocorticoid use, whereas others remain unclear. Consensus is emerging about strategies to prevent AFFs in BP users (including drug holidays after 5 years' use in some patients). In conclusion, AFFs can be devastating, but even under the most pessimistic assumptions, the benefit/risk ratio is highly positive for BPs, particularly during 3 to 5 years of use. As understanding of AFFs increases, it is becoming increasingly possible to maximize BP benefits while minimizing AFF risk.

Original languageEnglish
Pages (from-to)333-368
Number of pages36
JournalEndocrine Reviews
Volume40
Issue number2
DOIs
Publication statusPublished - Jan 1 2019

Fingerprint

Diphosphonates
Femur
Epidemiology
Bone and Bones
Fracture Fixation
Holidays
Hip Fractures
North America
Thigh
Drug Users
Glucocorticoids
Osteoporosis
Minerals
Meta-Analysis
Hip
Epidemiologic Studies
Odds Ratio

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

Atypical femur fractures : Review of epidemiology, relationship to bisphosphonates, prevention, and clinical management. / Black, Dennis M.; Abrahamsen, Bo; Bouxsein, Mary L.; Einhorn, Thomas; Napoli, Nicola.

In: Endocrine Reviews, Vol. 40, No. 2, 01.01.2019, p. 333-368.

Research output: Contribution to journalReview article

Black, Dennis M. ; Abrahamsen, Bo ; Bouxsein, Mary L. ; Einhorn, Thomas ; Napoli, Nicola. / Atypical femur fractures : Review of epidemiology, relationship to bisphosphonates, prevention, and clinical management. In: Endocrine Reviews. 2019 ; Vol. 40, No. 2. pp. 333-368.
@article{6fefee4278e74f8ca6196924e7d39de7,
title = "Atypical femur fractures: Review of epidemiology, relationship to bisphosphonates, prevention, and clinical management",
abstract = "Bisphosphonates (BPs) are highly effective in treating osteoporosis and reducing hip, vertebral, and other fractures by as much as 50{\%} to 70{\%}. However, since 2006, atypical femur fractures (AFFs) emerged as potential side effects of BPs and other treatments. These fractures have unusual radiologic features and occur with little trauma. Public concern has led to a >50{\%} decrease in BP usage. AFFs are rare: for each AFF, >1200 fractures, including 135 hip fractures, are prevented. Case definition criteria were updated by the American Society of Bone and Mineral Research in 2014. Many epidemiologic studies have been reported, and although methodologically challenging, generally support a BP-AFF association. However, the magnitude of the association between BPs and AFFs is uncertain: estimates of relative risk for AFFs among BP users vs nonusers range from 1 to 65 with a meta-analysis estimate of 1.7. Although mechanistic studies have proposed several hypotheses explaining how BPs might decrease bone strength, AFF pathogenesis remains uncertain and cannot explain the paradox of efficacy of reduction of common fractures while increasing risk for rare fractures at one site. There are several consistent risk factors, including Asian race (in North America), femoral bowing, and glucocorticoid use, whereas others remain unclear. Consensus is emerging about strategies to prevent AFFs in BP users (including drug holidays after 5 years' use in some patients). In conclusion, AFFs can be devastating, but even under the most pessimistic assumptions, the benefit/risk ratio is highly positive for BPs, particularly during 3 to 5 years of use. As understanding of AFFs increases, it is becoming increasingly possible to maximize BP benefits while minimizing AFF risk.",
author = "Black, {Dennis M.} and Bo Abrahamsen and Bouxsein, {Mary L.} and Thomas Einhorn and Nicola Napoli",
year = "2019",
month = "1",
day = "1",
doi = "10.1210/er.2018-00001",
language = "English",
volume = "40",
pages = "333--368",
journal = "Endocrine Reviews",
issn = "0163-769X",
publisher = "The Endocrine Society",
number = "2",

}

TY - JOUR

T1 - Atypical femur fractures

T2 - Review of epidemiology, relationship to bisphosphonates, prevention, and clinical management

AU - Black, Dennis M.

AU - Abrahamsen, Bo

AU - Bouxsein, Mary L.

AU - Einhorn, Thomas

AU - Napoli, Nicola

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Bisphosphonates (BPs) are highly effective in treating osteoporosis and reducing hip, vertebral, and other fractures by as much as 50% to 70%. However, since 2006, atypical femur fractures (AFFs) emerged as potential side effects of BPs and other treatments. These fractures have unusual radiologic features and occur with little trauma. Public concern has led to a >50% decrease in BP usage. AFFs are rare: for each AFF, >1200 fractures, including 135 hip fractures, are prevented. Case definition criteria were updated by the American Society of Bone and Mineral Research in 2014. Many epidemiologic studies have been reported, and although methodologically challenging, generally support a BP-AFF association. However, the magnitude of the association between BPs and AFFs is uncertain: estimates of relative risk for AFFs among BP users vs nonusers range from 1 to 65 with a meta-analysis estimate of 1.7. Although mechanistic studies have proposed several hypotheses explaining how BPs might decrease bone strength, AFF pathogenesis remains uncertain and cannot explain the paradox of efficacy of reduction of common fractures while increasing risk for rare fractures at one site. There are several consistent risk factors, including Asian race (in North America), femoral bowing, and glucocorticoid use, whereas others remain unclear. Consensus is emerging about strategies to prevent AFFs in BP users (including drug holidays after 5 years' use in some patients). In conclusion, AFFs can be devastating, but even under the most pessimistic assumptions, the benefit/risk ratio is highly positive for BPs, particularly during 3 to 5 years of use. As understanding of AFFs increases, it is becoming increasingly possible to maximize BP benefits while minimizing AFF risk.

AB - Bisphosphonates (BPs) are highly effective in treating osteoporosis and reducing hip, vertebral, and other fractures by as much as 50% to 70%. However, since 2006, atypical femur fractures (AFFs) emerged as potential side effects of BPs and other treatments. These fractures have unusual radiologic features and occur with little trauma. Public concern has led to a >50% decrease in BP usage. AFFs are rare: for each AFF, >1200 fractures, including 135 hip fractures, are prevented. Case definition criteria were updated by the American Society of Bone and Mineral Research in 2014. Many epidemiologic studies have been reported, and although methodologically challenging, generally support a BP-AFF association. However, the magnitude of the association between BPs and AFFs is uncertain: estimates of relative risk for AFFs among BP users vs nonusers range from 1 to 65 with a meta-analysis estimate of 1.7. Although mechanistic studies have proposed several hypotheses explaining how BPs might decrease bone strength, AFF pathogenesis remains uncertain and cannot explain the paradox of efficacy of reduction of common fractures while increasing risk for rare fractures at one site. There are several consistent risk factors, including Asian race (in North America), femoral bowing, and glucocorticoid use, whereas others remain unclear. Consensus is emerging about strategies to prevent AFFs in BP users (including drug holidays after 5 years' use in some patients). In conclusion, AFFs can be devastating, but even under the most pessimistic assumptions, the benefit/risk ratio is highly positive for BPs, particularly during 3 to 5 years of use. As understanding of AFFs increases, it is becoming increasingly possible to maximize BP benefits while minimizing AFF risk.

UR - http://www.scopus.com/inward/record.url?scp=85062084833&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85062084833&partnerID=8YFLogxK

U2 - 10.1210/er.2018-00001

DO - 10.1210/er.2018-00001

M3 - Review article

C2 - 30169557

AN - SCOPUS:85062084833

VL - 40

SP - 333

EP - 368

JO - Endocrine Reviews

JF - Endocrine Reviews

SN - 0163-769X

IS - 2

ER -